ARVN: Arvinas, Inc.
About
Arvinas, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its product candidates are ARV-110, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer, ARV-471, and ARV-766, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer. The company was founded in February 2013 and is headquartered in New Haven, CT.
Current Value
$21.591 Year Return
Current Value
$21.591 Year Return
Key Details
Market Cap
$1.49B
P/E Ratio
-4.63
1Y Stock Return
4.04%
1Y Revenue Growth
0.94%
Dividend Yield
0.00%
Price to Book
2.5
Strategies that include ARVN
Stock's related to ARVN
Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| PHR | 54.10% | $1.07B | +20.61% | 0.00% |
| ABCL | 50.70% | $800.44M | -37.56% | 0.00% |
| CRBU | 47.73% | $180.20M | -62.45% | 0.00% |
| FARO | 46.50% | $486.17M | +40.51% | 0.00% |
| BEAM | 43.37% | $2.09B | -9.52% | 0.00% |
| KFRC | 42.84% | $1.10B | -8.71% | 0.66% |
| GBIO | 42.48% | $92.84M | +20.87% | 0.00% |
| STHO | 41.83% | $150.51M | -5.99% | 0.00% |
| SCL | 41.57% | $1.69B | -6.79% | 2.01% |
| SDGR | 41.38% | $1.38B | -35.46% | 0.00% |
| CMCO | 41.15% | $1.03B | +3.66% | 0.78% |
| FBNC | 41.10% | $1.87B | +46.57% | 1.95% |
| EDIT | 41.07% | $204.72M | -75.49% | 0.00% |
| KYMR | 40.81% | $2.77B | +125.95% | 0.00% |
| OPEN | 40.68% | $1.14B | -31.62% | 0.00% |
| HBT | 40.60% | $753.01M | +23.37% | 3.51% |
| IIIN | 40.56% | $574.03M | -5.28% | 0.41% |
| BIGC | 40.37% | $473.42M | -31.75% | 0.00% |
| HFWA | 40.33% | $873.99M | +47.58% | 3.58% |
| TCBK | 40.33% | $1.55B | +31.56% | 2.74% |
Uncorrelated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| LFVN | 0.01% | $169.84M | +130.61% | 1.10% |
| SE | -0.01% | $60.12B | +197.12% | 0.00% |
| DOGZ | -0.03% | $614.77M | +1,372.26% | 0.00% |
| ERIE | -0.07% | $19.39B | +46.23% | 1.23% |
| APRE | 0.08% | $16.41M | -19.47% | 0.00% |
| IBN | 0.10% | $104.98B | +33.69% | 0.80% |
| KMB | 0.11% | $45.22B | +11.57% | 3.58% |
| YEXT | -0.12% | $996.50M | +15.58% | 0.00% |
| PG | 0.16% | $402.15B | +14.14% | 2.33% |
| BACK | -0.19% | $1.76M | -32.90% | 0.00% |
| ASUR | -0.21% | $233.14M | +12.13% | 0.00% |
| STNG | 0.22% | $2.96B | +0.87% | 2.75% |
| CCEC | 0.23% | $1.02B | +28.03% | 3.26% |
| NGL | -0.23% | $572.94M | +5.60% | 0.00% |
| XNET | 0.24% | $123.61M | +26.62% | 0.00% |
| RSG | -0.24% | $66.05B | +31.79% | 1.04% |
| PRPH | -0.24% | $18.14M | -82.61% | 0.00% |
| PRT | 0.25% | $48.72M | -16.56% | 10.33% |
| JNPR | -0.28% | $11.61B | +30.55% | 2.49% |
| TRGP | -0.29% | $44.39B | +132.49% | 1.34% |
Inversely Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| MCK | -17.71% | $78.15B | +35.51% | 0.42% |
| BTI | -16.42% | $81.54B | +16.13% | 8.08% |
| CME | -15.72% | $82.76B | +9.21% | 1.98% |
| CBOE | -14.43% | $21.46B | +15.84% | 1.11% |
| PGR | -13.57% | $149.10B | +57.29% | 0.45% |
| MNOV | -10.82% | $93.19M | +2.15% | 0.00% |
| PULM | -10.54% | $19.83M | +202.98% | 0.00% |
| VIRT | -10.02% | $3.17B | +110.38% | 2.60% |
| COR | -9.99% | $47.48B | +21.20% | 0.86% |
| AVAL | -9.73% | $791.37M | -4.11% | 7.14% |
| AJG | -9.47% | $64.17B | +17.51% | 0.80% |
| BTCT | -8.83% | $42.61M | +353.33% | 0.00% |
| CYD | -8.04% | $364.46M | -2.94% | 4.26% |
| MSDL | -7.69% | $1.83B | +0.66% | 7.26% |
| ACGL | -7.63% | $36.00B | +16.84% | 0.00% |
| TW | -7.62% | $28.66B | +42.39% | 0.29% |
| ARLP | -6.88% | $3.54B | +26.77% | 10.11% |
| AFL | -6.78% | $61.74B | +35.69% | 1.35% |
| RNR | -6.63% | $13.74B | +23.09% | 0.58% |
| LPLA | -6.54% | $23.55B | +38.13% | 0.38% |
ETF's related to ARVN
Correlated ETFs
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| RSPA | 54.00% | $273.87M | 0% |
| IWC | 50.08% | $933.99M | 0.6% |
| ARKG | 48.68% | $1.13B | 0.75% |
| IWM | 46.49% | $75.73B | 0.19% |
| VTWO | 46.20% | $12.38B | 0.1% |
| CGW | 46.11% | $962.52M | 0.56% |
| IFRA | 45.85% | $3.24B | 0.3% |
| IWN | 45.66% | $13.17B | 0.24% |
| PRFZ | 45.62% | $2.65B | 0.39% |
| GNOM | 45.55% | $70.59M | 0.5% |
| XHE | 45.41% | $213.41M | 0.35% |
| XPH | 44.85% | $157.87M | 0.35% |
| IWO | 44.82% | $12.56B | 0.24% |
| NUSC | 44.79% | $1.27B | 0.31% |
| KOMP | 44.75% | $2.09B | 0.2% |
| GSSC | 44.64% | $529.86M | 0.2% |
| ESML | 44.44% | $1.90B | 0.17% |
| EES | 44.17% | $668.71M | 0.38% |
| SLYV | 44.15% | $4.16B | 0.15% |
| FYX | 44.04% | $959.00M | 0.6% |
News
Yahoo
We recently compiled a list of the 10 Best Small-Cap Stocks Ready To Explode. In this article, we are going to take a look at where Arvinas, Inc. (NASDAQ:ARVN) stands against the other small-cap stocks. Prospects For Extended Outperformance Of Small-Cap Stocks On October 7, Chuck Royce, founder and Senior Advisor, and Francis Gannon, Co-Chief Investment […]
Yahoo
NEW HAVEN, Conn., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that management will participate in two upcoming investor conferences: Guggenheim Securities Healthcare Innovation Conference on Wednesday, November 13. Noah Berkowitz, MD, Ph.D. Chief Medical Officer, and Randy Teel, Ph.D., Chief Business Officer, will participate in a fireside chat. A live a
Yahoo
Arvinas ( NASDAQ:ARVN ) Third Quarter 2024 Results Key Financial Results Revenue: US$102.4m (up 196% from 3Q 2023). Net...
Yahoo
Arvinas Inc (ARVN) reports a significant revenue increase and outlines strategic advancements in its groundbreaking PROTAC platform and oncology pipeline.
SeekingAlpha
Arvinas, Inc. (NASDAQ:ARVN) Q3 2024 Earnings Conference Call October 30, 2024 8:00 AM ETCompany ParticipantsJeff Ball - Chief Financial OfficerJohn Houston...
Yahoo
Arvinas (ARVN) delivered earnings and revenue surprises of 22.73% and 45.09%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Disclaimer
Information on this page is obtained from our data provider, Xignite, an unaffiliated third party. Double believes the information shown here is reliable, but has not been verified and there is no guarantee that the information is accurate. We also show information based on calculations performed by Double using data from our provider. Double believes this information is reliable, but has not verified the data and there is no guarantee that the calculations are accurate.